Puma Biotechnology, Inc. PBYI
NASDAQ · United States · Health Technology
$9.84-0.09 (-0.91%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
LOS ANGELES, September 17, 2026--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
LOS ANGELES, September 09, 2026--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.
LOS ANGELES, September 03, 2026--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).
Moby summary of Puma Biotechnology, Inc.'s Q2 2026 earnings call
Puma Biotechnology Inc (PBYI) posts $8.2 million GAAP net income, raises full-year revenue and profit outlook, and advances its alisertib clinical program.
LOS ANGELES, August 06, 2026--Puma Biotechnology will host a conference call beginning at 1:30 p.m. PT on Aug. 6, following release of its earnings results for 2Q-2026.
LOS ANGELES, July 23, 2026--Puma Biotechnology will host a conference call at 1:30 p.m. PT on August 6, 2026, following release of its 2Q-2026 results.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.